Agent for increasing expression of intercellular adhesion molecule

JP2023068472A5Active Publication Date: 2024-11-07POLA CHEMICAL INDUSTRIES INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2021179618
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2021-11-02
Publication Date
2024-11-07
Estimated Expiration
2041-11-02

AI Technical Summary

Technical Problem

Existing technologies have not effectively addressed the decrease in intercellular adhesion function, leading to various disorders and diseases such as swelling by promoting the formation of tight junctions in epithelial tissues.

Method used

An intercellular adhesion factor expression-enhancing agent containing a supercritical CO2 extract of Rosa plants, particularly Rosa gallica and Rosa jurlique, is used to promote the expression of tight junction proteins like Zonula occludens-1 (ZO-1), enhancing cell adhesion.

Benefits of technology

The agent strengthens intercellular adhesion, improving the barrier function of epithelial tissues and preventing or ameliorating diseases like swelling by increasing the expression of tight junction proteins.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2023068472000001
    Figure 2023068472000001
Patent Text Reader

Abstract

To provide a novel agent for increasing the expression of intercellular adhesion molecules.SOLUTION: An agent for increasing the expression of intercellular adhesion molecules comprises extract from plants belonging to Rosa, Rosaceae, as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to an agent for enhancing the expression of an intercellular adhesion factor. [Background technology]

[0002] In the epithelial tissue of the skin, epithelial cells tightly bind to each other to form a cell layer. Epithelial cell adhesion is composed of cell adhesion structures such as tight junctions (TJs), adherens junctions (AJs), and desmosomes (DSs). Of these, tight junctions exist to function as a barrier between epithelial cells that come into contact with the outside world and prevent harmful substances from penetrating into the cells. The factors that make up tight junctions are known to be the cell membrane proteins claudins and occludin, and Zonula occludens protein, which binds to these proteins.

[0003] It is known that the factors that make up such tight junctions are deeply involved in maintaining homeostasis by functioning as a barrier separating the inside and outside of tissues in endothelial cells of blood vessels, lymphatic vessels, etc. If the factors that make up tight junctions are reduced, the structure of the tight junctions is destroyed, causing various diseases. For example, it has been revealed that the localization of Zonula occludens protein-1 (ZO-1) is involved in angiogenesis and endothelial barrier formation (Non-Patent Document 1).

[0004] The present inventors have also discovered that the presence of cortisol reduces intercellular adhesion between vascular endothelial cells and lymphatic vessel cells (Non-Patent Document 2). Based on this finding, it is believed that when cortisol levels increase due to stress, intercellular adhesion decreases, causing water to leak from blood vessels and lymphatic vessels, leading to water accumulation in the skin and swelling.

[0005] In recent years, in order to prevent and improve such diseases, etc., components that promote the formation of tight junctions in epithelial tissues have been sought. For example, a tight junction formation promoter containing mandarin orange extract as an active ingredient (Patent Document 1), an epithelial tight junction formation promoter containing processed garlic extract with a high concentration of sulfur-containing garlic components as an active ingredient (Patent Document 2), and an intercellular adhesion reduction inhibitor containing peach kernel (Prunus persica Batsch) extract as an active ingredient (Patent Document 3) have been disclosed. [Prior art documents] [Patent documents]

[0006] [Patent Document 1] Japanese Patent Application Publication No. 2016-222558 [Patent Document 2] Japanese Patent Application Laid-Open No. 2016-113368 [Patent Document 3] Japanese Patent Publication No. 2020-132546 [Non-patent literature]

[0007] [Non-Patent Document 1] Olga Tornavaca et al. J Cell Biol (2015) 208 (6): 821 838 [Non-patent document 2] "Stress hormones cause facial swelling," [online], June 28, 2019, Pola Orbis Holdings Co., Ltd., [searched September 14, 2021], Internet<http: / / www.pola-rm.co.jp / pdf / release_20190628.pdf> Summary of the Invention [Problem to be solved by the invention]

[0008] As mentioned above, it has become clear that a decrease in intercellular adhesion function causes various disorders in the body. Therefore, an object of the present invention is to provide a novel agent for enhancing the expression of an intercellular adhesion factor. [Means for solving the problem]

[0009] The present invention, which solves the above-mentioned problems, provides an agent for enhancing the expression of an intercellular adhesion factor, which comprises, as an active ingredient, an extract of a plant belonging to the genus Rosa of the family Rosaceae. The agent for enhancing the expression of an intercellular adhesion factor of the present invention can promote the expression of an intercellular adhesion factor and strengthen intercellular adhesion, and is also useful for preventing or ameliorating a decline in biological functions caused by a decline in intercellular adhesion function.

[0010] In a preferred embodiment of the present invention, the extract is obtained by supercritical CO2 extraction. The extract obtained by supercritical CO2 extraction is highly effective in promoting the expression of intercellular adhesion factors and strengthening intercellular adhesion.

[0011] In a preferred embodiment of the invention, the extract is based on hydrocarbon waxes. Rose extract, which contains hydrocarbon wax as its main component, is highly effective in promoting the expression of intercellular adhesion factors and strengthening intercellular adhesion.

[0012] In a preferred form of the invention, the present invention is used to promote cell-cell adhesion in blood and / or lymphatic vessels.

[0013] In a preferred embodiment of the present invention, the present invention is used for preventing and / or improving swelling.

[0014] In a preferred embodiment of the present invention, the present invention is used to improve skin condition.

[0015] In a preferred embodiment of the present invention, the intercellular adhesion factor is a tight junction-associated factor.

[0016] In a preferred embodiment of the present invention, the tight junction-associated factor is tight junction protein-1 (Zonula occludens-1, ZO-1). By setting the content within the above range, the effect of strengthening adhesion between cells is more pronounced.

[0017] The present invention also relates to an external skin preparation for increasing the expression of an intercellular adhesion factor, comprising the above-mentioned agent for increasing the expression of an intercellular adhesion factor. The topical skin preparation of the present invention can promote the expression of intercellular adhesion factors and strengthen intercellular adhesion. [Effects of the Invention]

[0018] The agent for enhancing the expression of an intercellular adhesion factor of the present invention can enhance the expression of an intercellular adhesion factor, and by strengthening intercellular adhesion, the agent for enhancing the expression of an intercellular adhesion factor of the present invention exhibits the effect of preventing or ameliorating diseases such as a decrease in the barrier function of epithelial tissue and swelling caused by a decrease in intercellular adhesion. [Brief explanation of the drawings]

[0019] [Figure 1] 1 shows immunohistochemical staining photographs showing ZO-1 protein expression in lymphatic endothelial cells without (a) addition of rose supercritical CO2 extract and with (b) addition of 0.1% rose extract in Test Example 1. ZO-1 is observed between cells and the presence of nuclei within the cells. The scale bar in the photographs is 100 μm. [Figure 2] 2 is a graph showing the calculated area ratio of the ZO-1 protein stained area per single area in the immunohistochemical staining image of FIG. 1. [Figure 3] 1 shows immunohistochemical staining photographs showing ZO-1 protein expression in vascular endothelial cells without (a) addition of rose supercritical CO2 extract and with (b) addition of 0.1% rose supercritical CO2 extract in Test Example 2. ZO-1 is observed between cells and within nuclei. The scale bar in the photographs is 100 μm. [Figure 4]4 is a graph showing the calculated ratio of the area occupied by ZO-1 protein stained areas per single area in the immunohistochemical staining image of FIG. 3. DETAILED DESCRIPTION OF THE INVENTION

[0020] (1) Extracts from plants belonging to the genus Rosa in the family Rosaceae The agent for enhancing expression of an intercellular adhesion factor of the present invention contains an extract of a plant belonging to the genus Rosa in the family Rosaceae (hereinafter simply referred to as rose extract). Examples of plants of the genus Rosa in the family Rosaceae include Rosa Jurlique, Rosa damascena, Rosa multiflora, Rosa centifolia, Rosa rugosa, Rosa chinensis, Rosa moschata, Rosa alba, Rosa alpina, Rosa canina, Rosa cinnamonea, Rosa gallica, Rosa repens, Rosa rubrifolia, Rosa rubiginosa, Rosa sempervirens, Rosa spinosissima, Rosa styosa, Rosa tomentosa, and Rosa villosa, with Rosa Jurlique and Rosa gallica being particularly preferred.

[0021] The part of the plant belonging to the genus Rosa to be extracted can be appropriately selected depending on the purpose, and examples thereof include leaves, stems, flowers, fruits, roots, etc. In the present invention, it is preferable to use flowers, particularly petals.

[0022] For extraction, it is preferable to dry the part of the plant belonging to the genus Rosa to be extracted in advance. In the present invention, the part is preferably freeze-dried or hot-air dried before being subjected to the extraction procedure.

[0023] Examples of extraction methods include immersing the plant in an extraction solvent at normal pressure, under pressure, or under reduced pressure at room temperature, or in a cooled or heated state; extraction using a distillation method such as steam distillation; squeezing the part to be extracted to obtain an extract; and supercritical fluid extraction. In the present invention, extraction by supercritical fluid extraction is preferred.

[0024] When extraction is carried out by supercritical fluid extraction, propane, ethylene, water, etc. can be used as the supercritical fluid, but in the present invention, it is preferable to use carbon dioxide.

[0025] Supercritical fluid extraction using carbon dioxide (supercritical CO2 extraction) is preferably carried out under conditions of a temperature of 40 to 90°C, a pressure of 8 to 60 MPa, and a CO2 flow rate of at least 20 times the weight of the petals charged. By performing supercritical fluid extraction under these conditions, a solid active ingredient (hereinafter also referred to as the solid ingredient) can be obtained.

[0026] The agent for enhancing the expression of an intercellular adhesion factor of the present invention can use the above-mentioned solid component as the rose extract of the present invention.

[0027] The rose extract according to the present invention is preferably a viscous wax, and preferably contains hydrocarbon wax as its main component, particularly paraffin wax as its main component. In the present invention, a component whose content ratio relative to the total amount of rose extract is 50% or more is determined to be a major component. The content ratio of a component can be expressed, for example, as an area percentage (%) measured by gas chromatography.

[0028] The paraffin wax preferably contains linear saturated hydrocarbons (n-paraffins) as the main component. The linear saturated hydrocarbons preferably have 20 to 35 carbon atoms, more preferably 23 to 33 carbon atoms. The content of saturated hydrocarbons having 20 to 35 carbon atoms is preferably 50 to 80%, more preferably 60 to 70%, based on the total amount of the rose extract.

[0029] In the present invention, the content of each component of the rose extract is expressed as the value of the component ratio (area percentage) measured by gas chromatography.

[0030] Furthermore, the paraffin wax preferably contains one or more selected from heptacosane, nonacosane, hentriacontane, and pentacosane, and more preferably contains heptacosane and one or more selected from nonacosane, hentriacontane, and pentacosane.

[0031] The rose extract preferably contains one or more selected from sitosterol, amylenol, and geranyl stearate, and the content of each of sitosterol, amylenol, and geranyl stearate is preferably 0.5 to 6%, more preferably 1 to 5%, based on the total amount of the rose extract.

[0032] In the present invention, it is preferable to dissolve the solid rose extract obtained by supercritical fluid extraction in an oil agent to obtain a liquid extract (hereinafter also referred to as rose extract).

[0033] The oil agent for dissolving the solid component is not particularly limited as long as it can solubilize the solid component. In the present invention, it is preferable to use a solution in which one or more selected from dicaprylyl carbonate, olive oil, and tri(caprylic / capric acid)glyceryl are mixed, and it is more preferable to use a solution in which equal amounts of dicaprylyl carbonate, olive oil, and tri(caprylic / capric acid)glyceryl are mixed.

[0034] The above-mentioned rose extract and the oil are preferably mixed under heating, specifically, at 40° C. Furthermore, it is preferable to carry out stirring and mixing for 10 minutes or more.

[0035] After stirring and mixing, the resulting rose extract is cooled and filtered using a mesh or the like to obtain the desired rose extract. The rose extract thus obtained, or an appropriately concentrated version thereof, can be used as an agent for enhancing the expression of an intercellular adhesion-promoting factor of the present invention.

[0036] The content of rose extract relative to the total amount of the intercellular adhesion factor expression enhancer of the present invention is preferably 0.001 to 10 mass%, more preferably 0.01 to 10 mass%, even more preferably 0.05 to 5 mass%, and particularly preferably 0.1 to 1 mass%, based on the dry mass.

[0037] (2) Intercellular adhesion factor Intercellular adhesion factors are proteins that form cell-to-cell adhesion. Preferred examples of intercellular adhesion factors in the present invention include factors associated with tight junctions between cells, such as claudins and occludins, which are skeletal proteins of tight junctions, and zonula occludens proteins, which bind to these proteins and form a lining structure.

[0038] Examples of tight junction proteins include Zonula occludens protein-1 (ZO-1), Zonula occludens protein-2 (ZO-2), and Zonula occludens protein-3 (ZO-3). The agent for enhancing the expression of an intercellular adhesion factor of the present invention is particularly effective in enhancing the expression of ZO-1.

[0039] Furthermore, the agent for enhancing the expression of an intercellular adhesion factor of the present invention has the effect of promoting the expression of an intercellular adhesion factor in epithelial tissue. The present invention is particularly effective in enhancing the expression of an intercellular adhesion factor in cells of blood vessels or lymphatic vessels among epithelial tissues.

[0040] (3) Dosage form The agent for enhancing the expression of an intercellular adhesion factor of the present invention may be administered in its undiluted form to the body, or may be diluted to any desired concentration before use. Furthermore, the agent for enhancing the expression of an intercellular adhesion factor of the present invention can be formulated in the form of an external skin preparation or an oral preparation by appropriately combining it with any desired components used in formulation. In the present invention, the agent for enhancing the expression of intercellular adhesion factors is preferably in the form of an external preparation for skin.

[0041] Examples of topical skin preparations include cosmetics, quasi-drugs, and topical skin medicines, with cosmetics and quasi-drugs being more preferred because they can be used daily. There are no particular limitations on the dosage form of these preparations. When used as a cosmetic, it is preferably in the form of a lotion, emulsion, gel, cream, ointment, etc. More specifically, it may be in the form of a lotion, emulsion, serum, cream, gel, pack, hair cream, spray, etc., and it is particularly preferably in the form of a lotion, emulsion, cream, or serum.

[0042] When the agent for enhancing the expression of an intercellular adhesion factor of the present invention is used as an oral preparation, it is preferably in the form of a food composition containing the agent for enhancing the expression of an intercellular adhesion factor of the present invention as an active ingredient, more specifically, in the form of a supplement having the dosage form of a general food, tablet, granule, drink, or the like.

[0043] When the intercellular adhesion factor expression enhancer of the present invention is used in an external skin preparation, the intercellular adhesion factor expression enhancer of the present invention can be contained in an amount of preferably 0.01 to 10% by mass, more preferably 0.05 to 5% by mass, and even more preferably 0.1 to 5% by mass, relative to the total amount of the external skin preparation. Furthermore, the content (dry mass) of rose extract in the topical skin preparation of the present invention is preferably 0.0001 to 0.1 mass%, more preferably 0.0005 to 0.05 mass%, and even more preferably 0.001 to 0.05 mass%, based on the mass of the plant extract after the solvent has been removed (dry mass), relative to the total mass of the topical skin preparation. It is believed that if the concentration is equal to or higher than the lower limit, the effect of the topical skin preparation of the present invention will be exhibited, and if the concentration is equal to or lower than the upper limit, the plateau of the effect can be avoided.

[0044] (4) Other ingredients The following describes ingredients that can be included in topical skin preparations such as cosmetics. For example, oily ingredients such as hydrocarbons, esters, triglycerides, fatty acids, and higher alcohols, surfactants such as anionic surfactants, amphoteric surfactants, cationic surfactants, and nonionic surfactants, polyhydric alcohols, thickeners / gelling agents, antioxidants, UV absorbers, colorants, preservatives, and powders can be optionally blended. Furthermore, as long as the effect of the agent for enhancing the expression of an intercellular adhesion factor of the present invention is not impaired, the agent may contain other active ingredients in addition to the agent for enhancing the expression of an intercellular adhesion factor of the present invention. The active ingredients include, but are not limited to, whitening ingredients, anti-wrinkle ingredients, anti-inflammatory ingredients, and extracts derived from animals and plants.

[0045] The topical skin preparation of the present invention can be prepared by treating the intercellular adhesion factor expression promoter of the present invention and the optional ingredients described above by a conventional method.

[0046] The agent for increasing the expression of intercellular adhesion factors of the present invention can be used to prevent or improve diseases caused by intercellular adhesion and deterioration of skin conditions, and is particularly suitable for use in diseases and deterioration of skin conditions caused by a decrease in the barrier function of epithelial cells or endothelial cells due to weakening of tight junctions between cells.

[0047] It is also thought that decreased cell adhesion in blood vessels and lymphatic vessels causes water to leak from these vessels, leading to water accumulation inside the skin and swelling. Therefore, the agent for enhancing the expression of intercellular adhesion factors of the present invention can be used to prevent or improve various diseases caused by leakage of body fluids due to instability of the duct structure, such as swelling, by strengthening intercellular adhesion in blood vessels or lymphatic vessels. That is, in a preferred embodiment of the present invention, the present invention can be used to promote intercellular adhesion in blood vessels and / or lymphatic vessels, and can also be used to prevent and / or improve swelling.

[0048] In addition, reduced intercellular adhesion and stagnation of blood and lymph flow due to swelling are thought to affect fluid exchange and oxygen supply within tissues, causing skin problems. Therefore, in a preferred embodiment of the present invention, the present invention can be used to improve skin condition. In the present invention, "improving skin condition" refers to suppressing deterioration and / or improving skin condition, and skin condition includes skin texture, sagging, elasticity, flexibility, rough skin, skin color, etc.

[0049] The topical skin preparation of the present invention is also preferably in a form labeled with the use indication "for promoting the expression of intercellular adhesion factors." The use indication may also be "for preventing and / or improving swelling," "for improving skin," etc.

[0050] The "indication" includes all indications that have the function of informing consumers of the intended use. In other words, any indication that can recall or infer the intended use falls under the category of "indication," regardless of the purpose of the indication, the content of the indication, the object or medium on which it is displayed, etc. Furthermore, the phrase "labeled" means that there is a labeling act that attempts to associate the label with the topical skin preparation (product).

[0051] The labeling act is preferably one that allows consumers to directly recognize the intended use. Specific examples include the act of describing the intended use on the product or product packaging of the cell preparation of the present invention, or the act of describing the intended use in product advertisements, price lists, or transaction documents (including those provided by electromagnetic means). [Example]

[0052] The present invention will be specifically described below with reference to examples, but these are merely examples of the present invention and the scope of the present invention is not limited to these examples.

[0053] <Production Example 1> Production of rose supercritical CO2 extract (1) Extraction of active ingredients 15 kg of dried rose (Rosa Jurlique) petals were placed in a supercritical CO2 reactor and the pressure was increased to 45 MPa. The extract was then extracted at 80°C, 45 MPa, and a CO2 flow rate 60 times the weight of the petals. Next, the pressure in the supercritical CO2 receiving tank was reduced to 5.5 MPa, and the inside of the piping was evacuated to 0 MPa. After reducing the pressure, the lid of the layered part of the separation tank was opened, and the wax component (solid extract) remaining at the bottom of the separation tank was collected using a scraping tool.

[0054] (2) Extraction of extracts The oil solutions shown in Table 1 below were weighed out and mixed to homogenize, thereby obtaining mixed oil solutions.

[0055] [Table 1]

[0056] The oil mixture was added to the extract obtained by supercritical CO2 extraction. After addition, the mixture was heated to 40°C and stirred for 10 minutes.

[0057] The resulting solution was stored in a refrigerator at 5° C. for 24 hours. Thereafter, the solution was filtered using a 1000 mesh filter, and the filtered extract (hereinafter referred to as rose extract) was collected.

[0058] (3) Analysis of extract components The wax component obtained in (1) above was analyzed using gas chromatography. The peak area of ​​each component was then calculated, and the area percentage (%) of each component was determined. As a result, the wax component contained 67.55% n-paraffins of C23 to C33 in total. The n-paraffins included C23, C25, C27 to C29, C31, and C33. Additionally, the wax component contained 3.6% sitosterol, 2.56% amylenol, and 2.07% geranyl stearate.

[0059] <Test Example 1> Analysis of tight junction-related factor expression in lymphatic endothelial cells using rose supercritical CO2 extract Using the rose extract obtained in Production Example 1, the effect of the rose extract on intercellular adhesion in lymphatic endothelial cells was evaluated.

[0060] (1) Cell preparation Human lymphatic endothelial cells (HLEC) (ScienCell Research Laboratories) were seeded in a flask containing Endothelial Cell Medium (ScienCell Research Laboratories) and cultured at 37°C and 5% CO2. Next, HLECs were placed in a 4-well slide chamber at 4.0 × 10 4 The cells were seeded at 100 cells / well and cultured for 48 hours.

[0061] Rose extract was added to a new endothelial cell medium to a concentration of 0.1% (0.001% dry mass). After 48 hours of culture, the medium for HLECs was replaced with medium containing the extract and cultured for 5 days. As a control, the following solution was added to HLECs instead of the rose supercritical CO2 extract and cultured for 5 days. Control solution: a mixture of 33% by weight of dicaprylyl carbonate, 33% by weight of caprylic / capric triglyceride, and 33% by weight of olive fruit oil

[0062] (2) Cell fixation and immunohistochemical staining The collected lymphatic endothelial cells were washed with PBS and fixed with 4% paraformaldehyde for 10 minutes. After washing with PBS, the cells were permeabilized by adding PBS containing 0.5% Triton X-100 and incubating for 10 minutes, and then blocked with 10% Block Ace for 30 minutes.

[0063] Subsequently, immunohistochemical staining was performed using the following antibodies. Specifically, lymphatic endothelial cells were washed with PBS, then primary antibodies were added and cultured overnight at 4°C. After washing again with PBS, secondary antibodies were added and cultured at room temperature for 30 minutes. Nuclear staining and slide mounting were then performed using Dapi-Fluoromount-G (registered trademark) (Southern Biotechnology Associates, Inc.). (antibody) Primary antibody: Rabbit anti-ZO-1 (200-fold diluted with 10% Block Ace) (Invitrogen) Secondary antibody: Alexa Fluor 488 (250-fold diluted with 10% Block Ace) (Invitrogen)

[0064] The obtained lymphatic endothelial cells were observed using a fluorescence microscope (KEYENCE BZ-X800), and images were taken for analysis. The results are shown in Figure 1.

[0065] (3) Expression analysis of tight junction-related factors Using the image editing software Image J (National Institutes of Health), three randomly selected areas were selected from the images taken by the fluorescence microscope. The percentage of the area occupied by the ZO-1 protein staining area per single area was calculated as the cell-cell adhesion area (%). The results are shown in Figure 2.

[0066] (4) Results 1 and 2, it was found that the expression of ZO-1 protein was increased when the rose supercritical CO2 extract was added compared to when the extract was not added. Therefore, it was revealed that the rose supercritical CO2 extract has the effect of strengthening intercellular adhesion of lymphatic vessel cells due to the increased expression of tight junction-related factors.

[0067] <Test Example 2> Analysis of tight junction-related factor expression in vascular endothelial cells using rose supercritical CO2 extract Using the rose extract obtained in Production Example 1, the effect of the rose extract on intercellular adhesion in vascular endothelial cells was evaluated.

[0068] (1) Cell preparation Normal human umbilical vein endothelial cells (HUVECs) were seeded in a flask containing a low-serum liquid medium for growing normal human vascular endothelial cells (HuMedia-EG2) (Kurabo Industries, Ltd.) and cultured at 37°C and 5% CO2. Next, HUVECs were placed in a 4-well slide chamber at 3.0 × 10 4 The cells were seeded at 100 cells / well and cultured for 48 hours.

[0069] Rose extract was added to a new low-serum liquid medium for the growth of normal human vascular endothelial cells to a concentration of 0.1% (0.001% by dry mass). After 48 hours of culture, the medium for HUVECs was replaced with medium containing the extract, and the cells were cultured for 5 days. As a control, the same control solution as in Test Example 1 above was added to HUVECs and the cells were cultured for 5 days.

[0070] (2) Cell fixation and immunohistochemical staining Immunohistochemical staining of vascular endothelial cells was carried out in the same manner as in Test Example 1(2). The results of the fluorescent photographs are shown in FIG.

[0071] (3) Expression analysis of tight junction-related factors As in Test Example 1(3) above, the percentage of the area stained for ZO-1 protein in the image of Figure 3 was calculated using Image J. The results are shown in Figure 4.

[0072] (4) Results 3 and 4 show that when the rose supercritical CO2 extract was added, the expression of ZO-1 protein increased compared to when the extract was not added. Therefore, it was revealed that rose supercritical CO2 extract also exerts an effect of strengthening intercellular adhesion in vascular endothelial cells due to increased expression of tight junction-related factors.

[0073] <Production Example 2> Beauty serum containing rose supercritical CO2 extract as an active ingredient A cosmetic essence for external use on the skin was prepared according to the following formulation. Specifically, the ingredients were heated to 80°C, stirred and solubilized, and then stirred and cooled to obtain the cosmetic essence. The rose extract used was that obtained in Production Example 1. The dry mass of the rose extract (dry mass of the wax component) relative to the total weight of the cosmetic essence was 0.001%.

[0074] [Table 2]

[0075] The cosmetic serum produced by the above method can be used to enhance adhesion between cells in blood vessels and lymphatic vessels, prevent and / or alleviate swelling, and improve skin condition. [Industrial Applicability]

[0076] The present invention can be applied to pharmaceuticals, cosmetics, and the like.

Claims

1. An agent for enhancing the expression of intercellular adhesion factors, comprising an extract of a plant belonging to the genus Rosa of the family Rosaceae as an active ingredient.

2. The extract is 2 The agent for enhancing the expression of an intercellular adhesion factor according to claim 1, which is an extract obtained by extraction.

3. The agent for enhancing the expression of an intercellular adhesion factor according to claim 1 or 2, wherein the extract has hydrocarbon wax as its main component.

4. The agent for enhancing the expression of an intercellular adhesion factor according to any one of claims 1 to 3, which is used to promote intercellular adhesion in blood vessels and / or lymphatic vessels.

5. An agent for enhancing the expression of an intercellular adhesion factor according to any one of claims 1 to 4, which is used for preventing and / or improving swelling.

6. An agent for increasing the expression of an intercellular adhesion factor according to any one of claims 1 to 5, which is used to improve skin condition.

7. The agent for increasing the expression of an intercellular adhesion factor according to any one of claims 1 to 6, wherein the intercellular adhesion factor is a tight junction-associated factor.

8. The agent for enhancing the expression of an intercellular adhesion factor according to claim 7, wherein the tight junction-associated factor is tight junction protein-1 (Zonula occludens-1, ZO-1).

9. An external skin preparation for increasing the expression of an intercellular adhesion factor, comprising the agent for increasing the expression of an intercellular adhesion factor according to any one of claims 1 to 8.